Shots:
- Simcere has granted NextCure exclusive global rights to develop, manufacture, & commercialize SIM0505 to treat solid tumors, excl. Greater China, where Simcere will retain its rights
- As per the deal, Simcere will receive ~$745M in upfront, development, regulatory & sales milestones, along with net sales-based royalties up to double-digits outside of Greater China. NextCure also obtained a non-exclusive, global license of Simcere’s linker & TOPOi payload for its preclinical ADC, with Simcere receiving ADC rights in the Greater China
- SIM0505, a CDH6-targeting ADC featuring Simcere’s TOPOi payload, is being assessed in P-I dose-escalation trials in China, with US P-I trial expected to start by Q3’25 & initial P-I data anticipated by H1’26
Ref: GlobeNewswire| Image: NextCure & Simcere| Press Release
Related News:- Simcere Zaiming and TargetRx Team Up to Develop TGRX-326 for Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
